{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-003847","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.025900+00:00","generated_at":"2026-06-19T02:23:18.368942+00:00","sec_items":["4.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Acasti Pharma dismisses KPMG as auditor, appoints Ernst & Young","bullets":["Audit committee and board approved dismissal of KPMG on February 22, 2023.","KPMG's reports for fiscal years ended March 31, 2022 and 2021 were unqualified with no adverse opinions.","No disagreements or reportable events occurred between the company and KPMG during the relevant periods.","Board approved engagement of Ernst & Young LLP as new independent auditor for fiscal year ending March 31, 2023.","KPMG furnished a letter to the SEC agreeing with the company's disclosures."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-003847","json":"https://secwatch.observer/filing/0000950170-23-003847.json","markdown":"https://secwatch.observer/filing/0000950170-23-003847.md","text":"https://secwatch.observer/filing/0000950170-23-003847.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023003847/0000950170-23-003847-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023003847/acst-20230222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T02:23:18.368942+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2919f98f76c120c6ae5a708cd36fce87903dd58b","claim":"Grace Therapeutics, Inc. engaged Ernst & Young LLP as its auditor.","evidence_excerpt":"On February 22, 2023, in connection with the Company’s dismissal of KPMG, the Board approved the engagement of Ernst & Young LLP (“E&Y”) as its new independent registered public accounting firm to audit the Company’s financial statements for the fiscal year ending March 31, 2023.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023003847/0000950170-23-003847-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"Ernst & Young LLP"}],"fact_type":"auditor_change"},{"claim_id":"833af0a8a3d2b620aee3cdd7bf0431e10603e4f7","claim":"Grace Therapeutics, Inc. dismissed KPMG LLP as its auditor.","evidence_excerpt":"On February 22, 2023, the audit committee and board of directors (the “Board”) of the Company approved the dismissal of KPMG as the Company’s independent registered public accounting firm.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023003847/0000950170-23-003847-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"KPMG LLP"},{"label":"Successor","value":"Ernst & Young LLP"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}